Sana Biotechnology (SANA) Debt to Equity (2021 - 2026)

Sana Biotechnology's Debt to Equity history runs 5 years deep, the most recent figure standing at $0.45 for Q1 2026.

• In Q1 2026, Debt to Equity changed N/A year-over-year to $0.45; the TTM figure through Mar 2026 stood at $0.45 (changed N/A YoY), while the FY2025 annual figure was $0.25, changed N/A from the prior year.
• Debt to Equity came in at $0.45 for Q1 2026 at Sana Biotechnology, up from $0.25 in the prior quarter.
• In the past five years, Debt to Equity ranged from a high of $0.45 in Q1 2026 to a low of $0.07 in Q1 2022.
• A 4-year average of $0.17 and a median of $0.12 in 2022 frame the typical range for Debt to Equity.
• Across the five-year window, Debt to Equity jumped 57.15% in 2022 and surged 104.77% in 2023, its largest moves.
• Sana Biotechnology's Debt to Equity stood at $0.11 in 2022, then soared by 48.45% to $0.16 in 2023, then surged by 51.86% to $0.25 in 2025, then soared by 79.75% to $0.45 in 2026.
• According to Business Quant data, Debt to Equity over the past three periods registered $0.45, $0.25, and $0.16 for Q1 2026, Q4 2025, and Q2 2023 respectively.

Peer Comparison